Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | ODYSSEE study: fecal microbiota transplantation in AML

Florent Malard • 4 Apr 2019
EBMT 2019
Acute Myeloid Leukemia Leukemia

Here, Florent Malard, MD, PhD, from Hôpital Saint-Antoine, Paris, France, discusses the multicentre ODYSSEE study at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, which has been held in Frankfurt, Germany.

More from Florent Malard

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:04
Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard • 20 May 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals